Intercell is an innovative biotechnology company focused on the design and development of novel vaccines for the prevention and treatment of infectious diseases. Our products target markets with substantial unmet medical needs, and we aim to improve health conditions for millions of people worldwide.
Biotech Company of the Year – Scrip Award winner 2008
In December 2008, Intercell was awarded the Scrip Award for Biotech Company of the Year. The judging criteria included the Company’s pipeline, fund raising and cash position, licensing and partnership deals, and technology. (press release)
Intercell is committed to continually keep interested parties updated with the latest news. Please see our press releases and most up-to-date reports.
Intercell’s first product on the market is a Japanese Encephalitis vaccine. Other products in clinical testing include vaccines against Travelers’ Diarrhea, Hepatitis C, Tuberculosis and Staphylococcus aureus. Several vaccine candidates and antigens are also being assessed in pre-clinical testing.
Intercell’s team consists of the Management Board, the Supervisory Board and the Scientific Advisory Board. These groups, together with our associates, comprise experienced professionals and give Intercell unsurpassed perspective on the business and research challenges within the field of infectious diseases and vaccines.
Intercell AG operates in three countries with headquarters in Vienna, manufacturing facilities in Livingston, Scotland, and a site in Gaithersburg, USA.
Do not hesitate to contact us for additional information.